A Phase 1, Open-label, Randomized, Crossover Study to Assess the Effect of Different Types of Co-administered Oral Liquids on the Relative Oral Bioavailability of a JNJ 77242113 Tablet Formulation in Healthy Participants.
Phase 1
- Conditions
- Inflammatory ConditionsMedDRA version: 20.0Level: SOCClassification code: 10021428Term: Immune system disorders Class: 4Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- CTIS2024-515230-32-00
- Lead Sponsor
- Janssen Cilag International
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method